Ojemda 500 mg Weekly Dose Carton Pack
RxNorm 2690860

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2690860 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ojemda 500 mg Weekly Dose Carton Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Ojemda 500 mg Weekly Dose Carton Pack
AUI:12908600
View
SY
Ojemda 500 mg Weekly Dose Carton Pack, 5 Blister Cards, 4 Tablets Each
AUI:12908599
View
BPCK
{20 (tovorafenib 100 mg Oral Tablet [Ojemda]) } Pack [Ojemda 500 mg Once Weekly Carton]
AUI:12908598
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Ojemda 500 mg Weekly Dose Carton Pack
(Atom ID: 12908600)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ojemda 500 MG Weekly Dose Carton Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2690860
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12908600
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2690860
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Ojemda 500 mg Weekly Dose Carton Pack, 5 Blister Cards, 4 Tablets Each
(Atom ID: 12908599)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Ojemda 500 MG Weekly Dose Carton Pack, 5 Blister Cards, 4 Tablets Each
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2690860
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12908599
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2690860
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
BPCKPrescribable

Brand Name Pack (BPCK):
{20 (tovorafenib 100 mg Oral Tablet [Ojemda]) } Pack [Ojemda 500 mg Once Weekly Carton]
(Atom ID: 12908598)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{20 (tovorafenib 100 MG Oral Tablet [Ojemda]) } Pack [Ojemda 500 MG Once Weekly Carton]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2690860
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12908598
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
2690860
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Tovorafenib


Tovorafenib is used to treat certain types of low grade glioma that has not responded to other therapies or has returned in children 6 months of age or older. Tovorafenib is in a class of medications called kinase inhibitors. It works by stopping the tumor growth.
[Learn More]


* Please review the disclaimer below.